IPO Databook: Latigo Biotherapeutics (LTGO US) - Aug 2026

• Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines. Their initial focus is on musculoskeletal pain, utilizing Nav1.8 inhibitors.
• Latigo Biotherapeutics is a clinical-stage company developing non-opioid pain medicines. LTG-001 abdominoplasty trial met its primary endpoint, achieving ~50% greater analgesic effect than Vicodin.
• The company reported a net loss of $(22,961) thousand for the three months ended March 31, 2026, with an accumulated deficit of approximately $266.1 million.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.